XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue $ 60,827,000 $ 38,429,000
License Revenue [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 22,590,000 0
Development Revenue [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 11,762,000 14,587,000
Astellas Agreement [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 22,590,000 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 32,000 80,000
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 5,148,000 3,531,000
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue $ 5,819,000 $ 10,976,000